Please assess the completion status of the following clinical trial:

Trial Title: Study of Milnacipran for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria~Exclusion Criteria:~* psychiatric illness,~* depression,~* suicidal risk,~* substance abuse,~* pulmonary dysfunction,~* renal impairment,~* active cardiac disease,~* liver disease,~* autoimmune disease,~* cancer,~* inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, twice daily for 12 weeks
- Milnacipran (Type: EXPERIMENTAL): Milnacipran 100mg/day (50mg BID \[twice a day\])

Based on this trial design, predict the completion outcome and termination type (if applicable).